Scarica l'app Stockscreener
110.12
5.48%
-6.39
Precedente Chiudi:
$116.51
Aprire:
$117
Volume 24 ore:
251.73K
Relative Volume:
1.00
Capitalizzazione di mercato:
$1.58B
Reddito:
$1.30M
Utile/perdita netta:
$-49.30M
Rapporto P/E:
-26.42
EPS:
-4.1688
Flusso di cassa netto:
$-25.01M
1 W Prestazione:
+5.51%
1M Prestazione:
-3.61%
6M Prestazione:
+13.75%
1 anno Prestazione:
+370.20%
Intervallo 1D:
$109.59
$117.00
Intervallo di 1 settimana:
$100.00
$117.00
Portata 52W:
$20.20
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
110.12 | 1.67B | 1.30M | -49.30M | -25.01M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum - Yahoo Finance
Palvella Therapeutics, Inc. Balance Sheet – LSX:A40RA6 - TradingView
ETFs Investing in Palvella Therapeutics, Inc. Stocks - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA) - The Globe and Mail
Return on invested capital % of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Cash Flow – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Earnings and Revenue – LS:A40RA6 - TradingView
CapEx per share of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Revenue per share of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Diluted net income available to common stockholders of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Enterprise value to EBITDA ratio of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Non-controlling/minority interest of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Balance Sheet – LS:A40RA6 - TradingView
Current ratio of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Statistics – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Dividends – LS:A40RA6 - TradingView
Discontinued operations of Palvella Therapeutics, Inc. – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Financial Statements – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Revenue Breakdown – LS:A40RA6 - TradingView
Palvella Therapeutics, Inc. Income Statement – LS:A40RA6 - TradingView
Palvella Therapeutics (PVLA) price target increased by 33.50% to 178.50 - MSN
Palvella Therapeutics (PVLA) director receives 3,000 stock options grant - Stock Titan
Palvella Therapeutics (PVLA) director granted 3,000 stock options at $102.19 - Stock Titan
ResVita Bio adds dermatologist John Doux to board By Investing.com - Investing.com Nigeria
PVLA: All proposals, including board elections and equity plan amendment, were approved by majority vote - TradingView
PVLA: All proposals passed, including director elections and equity plan amendment; no questions submitted - TradingView
ResVita Bio adds dermatologist John Doux to board - Investing.com UK
PVLA: Positive phase III data, strong cash position, and expanding rare disease pipeline drive growth - TradingView
Dermatologist-investor John Doux joins ResVita Bio board - Stock Titan
H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270 - Moomoo
Palvella Therapeutics: Qtorin Continues Making Progress, So I Remain Bullish - Seeking Alpha
Palvella Therapeutics Says No Additional Efficacy Study Planned for Qtorin Rapamycin - Moomoo
Palvella completes pre-NDA meeting with FDA for rapamycin gel - Investing.com UK
The Prognosis For Palvella Therapeutics (NASDAQ:PVLA) - Seeking Alpha
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations - markets.businessinsider.com
Palvella completes pre-NDA meeting with FDA for rapamycin gel By Investing.com - Investing.com South Africa
Palvella Therapeutics Advances QTORIN™ Rapamycin Toward NDA Submission for Microcystic Lymphatic Malformations in 2026 - Quiver Quantitative
Potential first treatment for rare disorder on track for 2026 FDA filing - Stock Titan
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - The Manila Times
Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240 - Moomoo
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Mizuho Securities Sticks to Their Buy Rating for Palvella Therapeutics (PVLA) - The Globe and Mail
Palvella Therapeutics Secures Patent Extending QTORIN™ Pitavastatin Market Exclusivity to 2043 for PROS Treatment - geneonline.com
Palvella secures U.S. patent for porokeratosis treatment - Investing.com UK
Palvella secures U.S. patent for porokeratosis treatment By Investing.com - Investing.com South Africa
Palvella Therapeutics Announces Issuance of U.S. Patent for QTORIN™ Pitavastatin in Treatment of Porokeratosis, Including DSAP - Quiver Quantitative
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 - The Manila Times
Kathleen Goin, Palvella COO, sells $475,630 in company stock By Investing.com - Investing.com India
Kathleen Goin, Palvella COO, sells $475,630 in company stock - Investing.com
Number of shareholders of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Palvella Therapeutics Inc Azioni (PVLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Goin Kathleen | Chief Operating Officer |
May 20 '26 |
Sale |
110.56 |
4,302 |
475,631 |
0 |
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):